Last reviewed: October 2026
It usually happens on an ordinary morning. You glance into the toilet and there it is: a small, pill-shaped object that looks exactly like the Concerta tablet you or your child swallowed yesterday. The first thought is almost always the same. The medicine went straight through. Nothing got absorbed. Was the whole day a wash? Finding a Concerta tablet in stool is one of the most common reasons people call a pharmacy about this drug, and in the large majority of cases the answer is reassuring. What you are most likely looking at is an empty shell, not a full dose.
That reassurance only makes sense once you know how the tablet is built. Concerta is not a pill that crumbles and dissolves in your stomach. It is a small pump, and pumps leave a housing behind. This article walks through that design layer by layer, then sorts the “this is expected” situations from the ones worth a phone call, and ends with a list of questions you can take to your pharmacist or prescriber.
The short version. Concerta is an osmotic tablet. Its outer shell does not break down, and the official prescribing information tells clinicians to advise patients not to be concerned if they occasionally see a tablet-like object in their stool. A shell that looks flattened, hollow, or lightweight is expected. A tablet that still seems full, a pattern of the medicine not lasting, very fast bowel transit, an ostomy, or any sign of a bowel blockage are reasons to talk with your pharmacist or prescriber. Concerta must be swallowed whole with liquid, never split, crushed, or chewed.
Inside the tablet: why a Concerta shell ends up in stool
Concerta is methylphenidate hydrochloride delivered through a system its maker calls OROS, short for osmotic release oral system. The brand’s US prescribing information (the version posted on the manufacturer’s site, revised September 2025) includes a section on “System Components and Performance” that describes the design. Picture it as a series of layers, from the outside in.
Layer 1: the immediate-release overcoat
The outermost coating is not just a color layer. It contains methylphenidate. According to the label, this drug overcoat dissolves within roughly the first hour after swallowing, giving an initial dose that starts working fairly quickly. Janssen’s medical information pages put the overcoat at about 22% of the total dose, which works out to roughly 4 mg in an 18 mg tablet, 6 mg in a 27 mg tablet, 8 mg in a 36 mg tablet, and 12 mg in a 54 mg tablet. The FDA label echoes the same split in a different section, noting that 22% of the methylphenidate is available for immediate release and 78% for extended release.
This is why pharmacokinetic studies in the label show methylphenidate levels reaching a first peak at about one hour. Once the overcoat is gone, the shell underneath is what you would see if you looked at the tablet a few hours later.
Layer 2: the semipermeable membrane
Under the overcoat is a rigid membrane. “Semipermeable” means it lets water in but does not let the drug simply leak out through its walls. The rate at which water crosses this membrane is what sets the pace of drug release. It is the speed governor of the whole system. Because the membrane is tough and does not dissolve, it is also the part most likely to show up later in the toilet.
Layers 3 and 4: two drug compartments
Inside the membrane sits what the label calls a trilayer core. Two of those three layers hold the remaining methylphenidate, roughly 78% of the dose. Janssen describes the two drug layers as having different concentrations, which helps shape the release so that blood levels climb gradually over the day rather than staying flat. The FDA label reports that after the first peak, concentrations keep rising for several hours, with average peak times falling between 6 and 10 hours across the different strengths. The company has not published the exact amount in each layer, citing proprietary reasons.
Layer 5: the push compartment
The third layer of the core contains no drug at all. It is made of polymers that are pharmacologically inactive but osmotically active, meaning they swell as they soak up water. As water seeps in through the membrane, this push layer expands like a slowly inflating balloon and presses against the drug layers.
Layer 6: the laser-drilled hole
At the drug-layer end of the tablet is a tiny opening made with a precision laser. As the push layer swells, the drug, now in a soft suspension, is squeezed out through this hole at a controlled rate. That is the whole trick: water in through the walls, medicine out through the hole, steadily, for hours. The FDA describes Concerta-equivalent products as releasing drug over about 10 to 12 hours, roughly matching what three separate doses of immediate-release methylphenidate would provide.
What is left at the end
When the drug layers are spent, the membrane and the swollen push material are still there. The prescribing information says plainly that these inert components are eliminated in the stool as a tablet shell, along with insoluble core components. The current Medication Guide puts it in patient terms: Concerta does not dissolve completely after the medicine has been released, and you or your child may sometimes notice the empty tablet in a bowel movement, which it calls normal. The clinician-facing counseling section goes a step further and tells prescribers to advise patients not to worry if they occasionally see a tablet-appearing substance in their stool.
The label also notes that the tablets can sometimes show up on abdominal X-rays. That is another clue to how sturdy the shell is. It is designed to survive the trip.
Pharmacists sometimes call these leftovers “ghost pills,” and a Concerta tablet in stool is a textbook example. A 2013 review in Therapeutic Advances in Drug Safety looked at this phenomenon across several controlled-release products, Concerta among them, and found that it often causes patients unnecessary anxiety mainly because nobody warned them it would happen. If you have been worried, you are in good company.
Normal vs worth a call
The shell’s whole purpose is to keep its shape, so an empty one can look surprisingly convincing. It may be roughly the same size and color as the original tablet. What tends to differ is how it feels and behaves if you look closely (wearing gloves, or simply by observation). Spent shells are often lighter, may look slightly collapsed or wrinkled, and can feel hollow or spongy rather than solid. Some people notice the small hole at one end.
You don’t need to inspect every bowel movement. If you spot a Concerta tablet in stool once in a while, that alone is not a problem. The table below is meant to help you decide whether what you saw fits the expected pattern or calls for a conversation.
| What you notice | What it usually means | Reasonable next step |
|---|---|---|
| Tablet-shaped object that looks hollow, light, flattened, or slightly crinkled; medicine seemed to work that day | The expected empty OROS shell. The label says this is not a cause for concern. | No action needed. Mention it at your next visit if you want reassurance. |
| Object that looks full, solid, and heavy, as if it never changed | Possible, though less common. The tablet may have moved through faster than usual, so less drug was released. | Call your pharmacist. Do not take an extra dose on your own. |
| Shells seen often, and symptoms seem poorly controlled, especially in the afternoon | Could reflect dose, timing, product differences, or GI transit. The shell alone does not tell you which. | Book a talk with your prescriber. Bring notes on timing and symptoms. |
| Tablet appears within a few hours of a dose, or during a bout of diarrhea | Rapid transit may cut release time short. | Let your pharmacist or prescriber know, especially if it keeps happening. |
| Ileostomy or colostomy, or a history of bowel surgery | Shells may appear in the pouch; very short transit may affect release. Narrowing is a separate concern. | Ask your prescriber whether Concerta is the best fit for your anatomy. |
| Belly pain, swelling, vomiting, or unable to pass stool or gas | Could signal a blockage. Rare, but serious. | Seek prompt medical care. |
| A child seems to have chewed or broken the tablet, or swallowed more than prescribed | The controlled-release design may be compromised. | Call your prescriber, or Poison Help at 1-800-222-1222. Use 911 for severe symptoms. |
Why a shell alone can’t tell you if the dose “worked”
Here is the part people find counterintuitive about a Concerta tablet in stool. An empty shell and a partly empty shell can look much alike, and nobody can reliably judge the amount of drug left inside by eye. That is why the better question is not “what does the shell look like?” but “how did the day go?” If focus, impulse control, and restlessness were managed the way they usually are, the medicine almost certainly did its job, whatever turned up later.
On the other hand, if you keep noticing that coverage fades early, or that some days feel like no dose was taken at all, that pattern deserves attention regardless of what is in the toilet. Write down a few days of observations: the time of the dose, when symptoms seemed to return, any diarrhea or stomach upset, and whether a shell was seen. Patterns are far more useful to a prescriber than a single sighting.
Fast transit, diarrhea, and ostomies
Because Concerta releases its drug over many hours while it travels through the gut, anything that dramatically shortens that journey could, in principle, cut release short. That includes a stomach bug, a flare of irritable bowel symptoms with diarrhea, or surgeries that shorten the intestine. The Concerta label itself does not quantify this effect, so it would be overstating things to say exactly how much drug is lost. Still, it is a reasonable topic to raise with a pharmacist, particularly if you have chronic diarrhea or an ileostomy.
People with ostomies may be more likely to actually see shells, since the pouch catches them. That alone is not a problem. The ghost-pill review mentioned above notes that, for other osmotic and controlled-release products, labeling explains that shells passed through a colostomy are generally not a concern because the drug has already been absorbed. If you have an ostomy, though, your prescriber also needs to know for a separate reason, which brings us to the narrowing warning.
A rigid tablet in a narrow gut: the label’s GI warning, swallowing rules, and generics
The same toughness that lets a Concerta shell survive the trip is also why the label carries a specific gastrointestinal caution. Understanding it puts the shell-in-stool question into context: the shell is normally harmless because a healthy gut moves it along. A gut with a tight spot is a different situation.
What the warning actually says
In the FDA label revised in February 2026, this appears as Warning 5.8, “Risk of Gastrointestinal Obstruction in Patients with Gastrointestinal Narrowing.” (Older versions of the label numbered it 5.9, so you may see either number depending on which copy you read.) The warning explains that Concerta tablets are nondeformable, meaning they do not noticeably change shape in the GI tract. It states that Concerta should not ordinarily be given to people with pre-existing severe GI narrowing, whether from disease or from surgery, and notes rare reports of obstructive symptoms in people with known strictures who took nondeformable controlled-release products. It adds that Concerta should only be used by people who can swallow the tablet whole.
MedlinePlus, the National Library of Medicine’s consumer site, translates this into a simple instruction: tell your doctor if you have narrowing or blockage of your digestive system. That might include a history of bowel strictures, certain types of intestinal surgery, or conditions your gastroenterologist has told you affect the width of your gut. If you are not sure, it is worth asking.
Symptoms that could suggest a blockage include crampy belly pain, a swollen or tight abdomen, vomiting, and being unable to pass stool or gas. These are not “watch and wait” symptoms. Get medical care promptly.
Why it has to go down whole, with liquid
The label’s dosing instructions are firm: swallow Concerta whole with liquids, and do not split, crush, or chew it. Looking back at the layers, the reasons are clear. Break the membrane and you break the speed governor. The drug layers are no longer released through one tiny hole at a pace set by water flow; they are exposed all at once. Janssen’s medical information says crushing or chewing compromises the delivery system and leaves the drug’s behavior in the body unpredictable. In practice that could mean a stronger early effect, more side effects, and coverage that runs out early.
This matters for misuse, too. Concerta carries a boxed warning that it has a high potential for abuse and misuse, which can lead to substance use disorder, including addiction, and that misuse can cause overdose and death. The label notes the risk is higher at higher doses and with unapproved routes such as snorting or injecting. Methylphenidate is a Schedule II controlled substance. Keep it stored securely, keep an eye on the count, and never share it.
If swallowing a whole tablet is hard, for a child or an adult, the Medication Guide asks you to tell your healthcare provider, who may prescribe a different medicine. Other methylphenidate formulations exist, and some are designed to be opened or taken differently, but switching is a prescriber decision because products are not interchangeable milligram for milligram. Our comparison of modafinil and methylphenidate covers some of the broader landscape, and our Concerta vs Adderall guide looks at how methylphenidate compares with amphetamine-based options.
A practical note on liquids: the label just says “with liquids,” and it says Concerta can be taken with or without food. In the label’s pharmacokinetic studies, a high-fat breakfast did not change how the drug performed. If you are taking other medicines in the morning, such as antacids or acid reducers, our article on Concerta and antacids explains what is and isn’t known about combining them.
Generic methylphenidate ER and the FDA’s bioequivalence review
Not every bottle labeled “methylphenidate ER” behaves exactly like brand Concerta, and the history here is worth knowing, because it is one of the few cases where the FDA publicly questioned whether approved generics matched their brand.
In November 2014, the FDA announced concerns about two generic versions of Concerta, made by Mallinckrodt and by Kudco Ireland. The review was prompted in part by adverse event reports describing the medicine not working well, especially later in the day. After re-examining the original data and running its own laboratory testing, the agency found that in some people these products appeared to release drug more slowly during the 7- to 12-hour window after dosing. The FDA said it had found no serious safety concern, but it changed the two products’ therapeutic equivalence rating from AB (substitutable) to BX, a designation meaning the data are insufficient to show equivalence. Practically, that meant pharmacies were no longer supposed to swap them in automatically for brand Concerta.
The FDA also revised its bioequivalence guidance for these tablets and asked both companies to either confirm equivalence under the new standards or withdraw voluntarily. When neither did, the agency proposed in October and November 2016 to withdraw approval of the two applications. The Federal Register notice for the Mallinckrodt product describes the core finding: drug exposure in the 7- to 12-hour window fell below the range the FDA accepts for bioequivalence. In the same period, the FDA noted that an authorized generic, which is Janssen’s own product sold under a different label, was not affected, and it approved another generic from Mylan in October 2016.
What does this mean for you today? A few careful points:
- The 2014 to 2016 actions were about two specific products, not generic methylphenidate in general. The generic market has changed since then, and your pharmacist can check the current FDA therapeutic equivalence rating for whatever product you are dispensed.
- The FDA’s own advice at the time was that patients should not change treatment except in consultation with a health professional, and that anyone noticing a loss of effect should contact the pharmacy to confirm which manufacturer’s product they received.
- Different manufacturers’ extended-release tablets can look different and may use different release technologies. Not all of them will leave the same kind of shell, or any visible shell. Seeing a Concerta tablet in stool, or not seeing one, is not evidence that a product is better or worse.
- If your symptom control changed around the time your refill looked different, that is a useful clue. Tell your prescriber and pharmacist the date of the change and what you noticed.
One more timing note. If the real issue is that a morning dose was delayed or forgotten, and that is why the afternoon felt rough, our guide to a missed morning dose of Concerta walks through what the patient information says and why late-day doses can affect sleep.
Questions to ask about a Concerta tablet in stool
When you find a Concerta tablet in stool and still feel unsure, pharmacists are often the fastest, easiest people to reach. Prescribers come in when a pattern points to a dosing or product change. These questions are written so you can read them off a phone screen at the counter or during a telehealth visit.
- “Is the product I’m getting brand Concerta, an authorized generic, or another manufacturer’s generic?” The answer tells you which design you are dealing with and whether a refill change could explain any difference you’ve noticed.
- “Does this particular product leave an empty shell, and what does that shell typically look like?” Pharmacists can describe it, and knowing what to expect takes a lot of the alarm out of the next sighting.
- “What is the current FDA therapeutic equivalence rating for this generic?” Pharmacists can look this up in the FDA’s Orange Book. It is a fair question given the history described above.
- “I saw what looked like a full tablet. Should I do anything about today’s dose?” Ask before acting. Don’t take an extra tablet to “make up” for one you think passed through; the label does not support that, and stimulant doubling can cause problems.
- “I have frequent diarrhea, IBS, or a shortened bowel. Could that affect how much medicine I get?” Your prescriber can weigh whether a different formulation makes more sense.
- “I have an ostomy, a past bowel surgery, or a known stricture. Is a nondeformable tablet safe for me?” This ties directly to the label’s GI narrowing warning.
- “My child has trouble swallowing tablets whole. What are our options?” The Medication Guide specifically asks families to raise this so the prescriber can consider another medicine.
- “The medicine seems to wear off early. What should I track before our next appointment?” Ask what timing details, symptoms, and side effects would be most useful for the prescriber to see.
- “Do any of my other medicines or supplements affect Concerta?” The label lists interactions such as MAO inhibitors (contraindicated with Concerta and within 14 days of stopping one), blood pressure medicines, certain anesthetics, and risperidone. A full medication review is worth doing once a year.
- “Which symptoms would mean I should stop and seek care right away?” Have them name the GI warning signs, plus the stimulant warnings in the Medication Guide such as chest pain, fainting, or new psychiatric symptoms.
If you would like help reaching a pharmacist about a prescription, you can use our contact page.
Frequently asked questions
Can I tell whether a shell is empty without handling it?
Not with certainty. Empty shells often look a bit deflated or wrinkled compared with a fresh tablet, but that sign isn’t reliable. Rather than fishing it out, focus on how well symptoms were controlled that day. If the day went as usual, the dose almost certainly delivered.
How soon after a dose could the shell show up?
It depends on your own gut transit time, which varies from person to person and day to day. There is no fixed timetable. A shell that appears within just a few hours of the dose, or during diarrhea, is worth mentioning to a pharmacist because the tablet may not have had its usual time to release.
My child’s generic doesn’t leave a shell but the brand did. Is one of them wrong?
Not necessarily. Different manufacturers may build their extended-release tablets differently, and some leave less visible residue. Absence of a shell doesn’t mean a product failed, and presence doesn’t mean it worked better. If you notice a change in how well symptoms are controlled after a switch, though, report it with the dates.
Is the shell harmful to pass?
For people with a normal digestive tract, no. It is designed to pass. The concern the label raises is for people with pre-existing severe narrowing of the gut, where a rigid tablet could contribute to a blockage. If you have any history of strictures or bowel surgery, make sure your prescriber knows.
Can I cut a Concerta tablet if the dose feels too strong?
No. The label says not to split, crush, or chew the tablets, because breaking the membrane defeats the controlled-release design. If the dose feels too strong or too weak, call your prescriber. Concerta comes in several strengths, and dose changes are their call.
Could the shell show up on an X-ray or imaging test?
Yes, possibly. The prescribing information notes that Concerta tablets may be visible on abdominal X-rays under certain circumstances. If you are having abdominal imaging, it is helpful to let the radiology team know you take an extended-release osmotic tablet.
Does upset stomach from Concerta relate to the shell?
Stomach upset and reduced appetite are common stimulant side effects that come from the medicine itself, not from the shell. Our separate guide to Concerta and nausea covers that side of things. New abdominal pain with vomiting or bloating is different and should be checked promptly.
References
- US Food and Drug Administration. CONCERTA (methylphenidate HCl) extended-release tablets: Prescribing Information and Medication Guide (revised 2/2026).
- Janssen Pharmaceuticals. CONCERTA Full Prescribing Information, including Section 11.1, System Components and Performance (revised 9/2025).
- US Food and Drug Administration. Methylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco.
- Federal Register. Mallinckrodt Pharmaceuticals; Proposal to Withdraw Approval of an Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets (October 18, 2016).
- MedlinePlus, National Library of Medicine. Methylphenidate (revised April 2026).
- Tungaraza TE, Talapan-Manikoth P, Jenkins R. Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Ther Adv Drug Saf. 2013;4(2):63–71.
For more articles on ADHD medicines and everyday medication questions, browse the Mediclox health blog.
This article is for general information and isn’t a substitute for advice from your prescriber or pharmacist. Concerta (methylphenidate) is a Schedule II controlled substance with a boxed warning for abuse, misuse, and addiction. Don’t change how you take it, adjust your dose, or switch products without talking to your healthcare provider. If you think someone has taken too much, call Poison Help at 1-800-222-1222, or 911 for an emergency.